share_log

啓明醫療-B：截至二零二四年三月三十一日止月份之股份發行人的證券變動月報表

VENUS MEDTECH-B: Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 March 2024

香港交易所 ·  Apr 3 06:01
Summary by Moomoo AI
杭州啓明醫療器械股份有限公司（啓明医疗-B）於2024年4月3日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年3月31日的股份變動情況。報告顯示，公司的普通股H類股份（股份代號02500）在香港聯交所上市的法定/註冊股本和已發行股份在本月內均無變動，結存總數維持在441,010,235股，每股面值1人民幣。此外，公司非上市外資股的數量也維持不變，為1,208股。公司確認，所有證券的發行均已獲得董事會的正式授權，並符合相關法律規定。報告由執行董事柳美榮呈交。
杭州啓明醫療器械股份有限公司（啓明医疗-B）於2024年4月3日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年3月31日的股份變動情況。報告顯示，公司的普通股H類股份（股份代號02500）在香港聯交所上市的法定/註冊股本和已發行股份在本月內均無變動，結存總數維持在441,010,235股，每股面值1人民幣。此外，公司非上市外資股的數量也維持不變，為1,208股。公司確認，所有證券的發行均已獲得董事會的正式授權，並符合相關法律規定。報告由執行董事柳美榮呈交。
HANGZHOU KAIMING MEDICAL DEVICES CO., LTD. (KAIMING MEDICAL-B) FILED ITS LATEST MONTHLY SECURITIES CHANGE REPORT WITH HONG KONG TRADING AND SETTLEMENT LIMITED ON APRIL 3, 2024, REPORTING THE STOCK CHANGES AS OF MARCH 31, 2024. THE REPORT SHOWS THAT THE STATUTORY/REGISTERED SHARE CAPITAL OF THE COMPANY'S ORDINARY CLASS H SHARES (SHARE CODE 02500) LISTED ON THE HONG KONG EXCHANGE AND THE ISSUED SHARES REMAINED UNCHANGED DURING THE MONTH, WITH A TOTAL DEPOSIT OF 441,010,235 SHARES WITH A FACE VALUE OF RMB 1 PER SHARE. In addition, the number of non-listed foreign shares of the company remained unchanged at 1,208 shares. The Company confirms that all issues of securities have been formally authorized by the Board of Directors and comply with the relevant legal requirements. The report was presented by the Executive Director, Mr. Liu Mei Wing.
HANGZHOU KAIMING MEDICAL DEVICES CO., LTD. (KAIMING MEDICAL-B) FILED ITS LATEST MONTHLY SECURITIES CHANGE REPORT WITH HONG KONG TRADING AND SETTLEMENT LIMITED ON APRIL 3, 2024, REPORTING THE STOCK CHANGES AS OF MARCH 31, 2024. THE REPORT SHOWS THAT THE STATUTORY/REGISTERED SHARE CAPITAL OF THE COMPANY'S ORDINARY CLASS H SHARES (SHARE CODE 02500) LISTED ON THE HONG KONG EXCHANGE AND THE ISSUED SHARES REMAINED UNCHANGED DURING THE MONTH, WITH A TOTAL DEPOSIT OF 441,010,235 SHARES WITH A FACE VALUE OF RMB 1 PER SHARE. In addition, the number of non-listed foreign shares of the company remained unchanged at 1,208 shares. The Company confirms that all issues of securities have been formally authorized by the Board of Directors and comply with the relevant legal requirements. The report was presented by the Executive Director, Mr. Liu Mei Wing.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more